EBV LMP2 356-364 (HLA-A*02:01)
( FLYALALLL )
Antigen Peptide EBV LMP2 HLA-A*0201 (FLYALALLL) for stimulation of human EBV LMP2(356-364)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele. LYALALLL is a linear peptidic epitope studied as part of Latent membrane protein 2 from Human herpesvirus 4 (Epstein Barr virus).
| Sequence: | FLYALALLL | |
| Gene: | LMP2 | |
| Delivery: | 1-3 days | |
| C-Terminus: | OH | |
| N-Terminus: | H | |
| Amount: | 1 mg | |
| Counter Ion: | TFA | |
| Protein: | Latent membrane protein | |
| Species: | Epstein-Barr virus (EBV; Human herpesvirus 4) | |
| Allele: | HLA-A*02:01 | |
| Application : | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response | |
| Indication : | Infectious disease, Cancer, Neuroscience | |
| Purity : | 95% HPLC-MS |
Protocols and Tips
Data sheets
Safety data sheet poly peptides:For your convenience, we have compiled a selection of publications
where our peptide products have been employed:
Publications >
€105.00*
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS
More EBV LMP peptides
